Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
复制标题
对患有过敏史的医务人员，对BNT162B2 mRNA Covid-19疫苗的不良反应。
DOI：
10.1016/j.resinv.2021.11.007
复制
发表时间：
2022-03
影响因子：
3.1
通讯作者：
Ueno Y
中科院分区：
文献类型：
--
作者：
Inoue S;Igarashi A;Morikane K;Hachiya O;Watanabe M;Kakehata S;Sato S;Ueno Y
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2、COVID-19）疫苗接种正在全球范围内取得进展。据报道，针对 COVID-19 的疫苗接种存在多种不良反应。目前尚不清楚过敏个体对 COVID-19 疫苗接种的不良反应是否严重。我们于2021年3月至8月为山形大学医院的医务人员注射了COVID-19疫苗。随后，我们进行了在线问卷调查，以调查接种后是否存在过敏和不良反应，并检查免疫后过敏和不良反应之间的关联。分别收集了第一次和第二次注射 BNT162b2 mRNA COVID-19 疫苗后 1586 至 1306 名参与者的反应。不良反应包括注射部位疼痛、注射部位肿胀、发烧、疲劳或不适、头痛、发冷、恶心、注射部位外肌肉疼痛和关节痛。与不过敏的参与者相比，过敏的参与者出现某些不良反应的频率及其严重程度更高，而且症状持续时间更长。尽管有几名参与者在第一次和第二次疫苗接种后前往急诊室接受治疗，但没有参与者被诊断出过敏反应。这项研究表明，过敏个体注射 BNT162b2 mRNA COVID-19 疫苗后出现不良反应的频率和严重程度较高；然而，没有观察到严重的不良反应，例如过敏反应或死亡。这些结果表明有过敏史的个体可能耐受 BNT162b2 mRNA COVID-19 疫苗。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) vaccination is progressing globally. Several adverse reactions have been reported with vaccination against COVID-19. It is unknown whether adverse reactions to COVID-19 vaccination are severe in individuals with allergies. We administered the COVID-19 vaccine to the medical staff at Yamagata University Hospital from March to August 2021. Subsequently, we conducted an online questionnaire-based survey to investigate the presence of allergy and adverse reactions after vaccination and examine the association between allergy and adverse reactions after immunization. Responses were collected from 1586 to 1306 participants after the first and second administration of the BNT162b2 mRNA COVID-19 vaccine, respectively. Adverse reactions included injection site pain, injection site swelling, fever, fatigue or malaise, headache, chills, nausea, muscle pain outside the injection site, and arthralgia. The frequency of some adverse reactions and their severity were higher, and the duration of symptoms was longer in participants with allergies than in those without allergies. Although several participants visited the emergency room for treatment after the first and second vaccinations, no participant was diagnosed with anaphylaxis. This study suggests that the frequency and severity of adverse reactions after injection of BNT162b2 mRNA COVID-19 vaccine were higher in individuals with allergy; however, no severe adverse reactions such as anaphylaxis or death were observed. These results indicate that individuals with allergic histories may tolerate the BNT162b2 mRNA COVID-19 vaccine.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
4.5
作者：
Lee YW;Lim SY;Lee JH;Lim JS;Kim M;Kwon S;Joo J;Kwak SH;Kim EO;Jung J;Kwon HS;Kim TB;Kim SH;Bae S
通讯作者：
Bae S
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
7.8
作者：
Nittner-Marszalska M;Rosiek-Biegus M;Kopeć A;Pawłowicz R;Kosińska M;Łata A;Szenborn L
通讯作者：
Szenborn L